AI Verdict
ERNAW has stronger fundamentals based on our AI analysis.
ERNAW vs ERAS Fundamental Comparison
| Metric | ERNAW | ERAS |
|---|---|---|
| Revenue | $582,000.0 | N/A |
| Net Income | $-14.1M | $-124.5M |
| Net Margin | -2,419.9% | N/A |
| ROE | -586.6% | -38.3% |
| ROA | -241.4% | -31.4% |
| Current Ratio | 1.01x | 10.04x |
| Debt/Equity | 0.22x | 0.00x |
| EPS | $-2.24 | $-0.44 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ERNAW vs ERAS: Frequently Asked Questions
Is ERNAW or ERAS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ERNAW has stronger fundamentals. ERNAW is rated STRONG SELL (95% confidence) while ERAS is rated STRONG SELL (92% confidence). This is not investment advice.
How does ERNAW compare to ERAS fundamentally?
Ernexa Therapeutics Inc. has ROE of -586.6% vs Erasca, Inc.'s -38.3%. Net margins are -2,419.9% vs N/A respectively.
Which stock pays higher dividends, ERNAW or ERAS?
ERNAW has a dividend yield of N/A or no dividend while ERAS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ERNAW or ERAS for long term?
For long-term investing, consider that ERNAW has STRONG SELL rating with 95% confidence, while ERAS has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ERNAW vs ERAS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ERNAW vs ERAS, the AI consensus favors ERNAW based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.